https://orcid.org/0000-0002-4141-6577
References
- Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136–1143. doi:10.1056/NEJMra2023911
- Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a Phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi:10.1016/j.jaad.2019.07.074
- Wang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration. J Am Acad Dermatol. 2021;84(4):1010–1014. doi:10.1016/j.jaad.2020.11.042
- Ruggiero A, Fabbrocini G, Cinelli E, et al. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–567. doi:10.1111/ced.14979
- Megna M, Cinelli E, Gallo L, et al. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res. 2022;314(6):619–623. doi:10.1007/s00403-021-02200-7
- Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. doi:10.1001/jamadermatol.2019.3336
- Al Hammadi A, Parmar NV. Erythema, pruritus, and diffuse peeling of skin during dupilumab therapy for atopic dermatitis in three adults. Int J Dermatol. 2019;58(1):e14–e15. doi:10.1111/ijd.14296
- Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339–1347. doi:10.1016/j.jaad.2021.01.012
- Heibel HD, Hendricks AJ, Foshee JP, et al. Rosacea associated with dupilumab therapy. J Dermatolog Treat. 2021;32(1):114–116. doi:10.1080/09546634.2019.1624683
- Dybała A, Sernicola A, Gomes V, et al. Dupilumab facial redness: histologic characterization on a series of four cases. Immunotherapy. 2022;14(4):183–188. doi:10.2217/imt-2021-0122
- Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47(5):918–925. doi:10.1111/ced.15052
- Labuz D, Celik M, Seitz V, et al. Interleukin-4 induces the release of opioid peptides from M1 macrophages in pathological pain. J Neurosci. 2021;41(13):2870–2882. doi:10.1523/JNEUROSCI.3040-20.2021
- Celik M, Labuz D, Keye J, et al. IL-4 induces M2 macrophages to produce sustained analgesia via opioids. JCI Insight. 2020;5(4). doi:10.1172/jci.insight.133093
- Singh SK, Krukowski K, Laumet GO, et al. CD8+ T cell-derived IL-13 increases macrophage IL-10 to resolve neuropathic pain. JCI Insight. 2022;7(5). doi:10.1172/jci.insight.154194